🔴 Humacyte is trading 5.5% down today, extending a multi-day slide amid dilution concerns and sector pressure

Humacyte is trading at $0.64 (5.5% down), extending a multi-day slide driven by prior dilution-related weakness and broader sector pressure.

• The decline follows recent equity offerings and dilution that have weighed on the stock's performance relative to the medical and biotech sectors.
• There are no fresh company-specific announcements for July 16; the move appears to be a continuation of risk-off sentiment in the biotech market rather than a new catalyst.